References

Cano et al (2020). Impact of corticosteroids in COVID-19 outcomes: systematic review and meta-analysis. Chest.

Draghici et al (2021). COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Bioinformatics (Oxford, England).

Evert et al (2021). Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. Virchows Archiv, 1-12.

Gandhi et al (2020). Mild or moderate Covid-19. New England Journal of Medicine, 383(18), 1757-1766.

Garg et al (2021). Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia, 1-10.

Garg, D et al (2021). Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia, 1-10.

Gaur et al (2021). An implant-supported prosthetic rehabilitation of a patient with a bilateral subtotal maxillectomy defect secondary to rhino-orbital-cerebral mucormycosis: A clinical report of a graftless approach. The Journal of Prosthetic Dentistry.

https://conferences.nature.com/event/801e647c-2ffa-4c98-ba1e-135d5cbf4991/summary

https://economictimes.indiatimes.com/news/international/world-news/british-variant-of-covid-19-not-as-severe-as-feared-according-to-the lancet/articleshow/82042830.cms?from=mdr

https://timesofindia.indiatimes.com/city/chennai/181-black-fungus-cases-so-far-in-tn/articleshow/82955642.cms

https://www.business-standard.com/article/current-affairs/india-reports-8-848-mucormycosis-cases-more-amphotericin-vials-allocated-121052200583_1.html

https://www.thehindu.com/opinion/op-ed/slowing-the-pace-of-indias-mucormycosis-threat/article34644652.ece/amp/

https://www.thenewsminute.com/article/tn-government-ropes-experts-study-black-fungus-or-mucormycosis-149492

Ibrahim et al (2007). The iron chelator deferasirox protects mice from mucormycosis through iron starvation. The Journal of clinical investigation, 117(9), 2649-2657.

John et al (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of Fungi, 7(4), 298.

John et al (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of Fungi, 7(4), 298.

Ko et al (2021). A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19. Journal of intensive care medicine, 0885066621994057.

Kontoyiannis  and Lewis (2011). How I treat mucormycosis. Blood, The Journal of the American Society of Hematology, 118(5), 1216-1224.

Kostova et al (2021). The Role of Noncommunicable Diseases in the Pursuit of Global Health Security. Health security.

Lamontagne et al (2020). A living WHO guideline on drugs for covid-19. bmj, 370.

Langarizadeh et al (2021). A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. EXCLI journal, 20, 339.

Lee et al (1999). Pulmonary mucormycosis: the last 30 years. Archives of Internal Medicine, 159(12), 1301-1309.

Marques et al (2021). The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf. Medical Mycology Case Reports.

Mazzai et al (2021). Imaging features of rhinocerebral mucormycosis: from onset to vascular complications. Acta Radiologica, 0284185120988828.

Miller et al (2021). Successful treatment of Rhizopus arrhizus rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement. Medical mycology case reports, 32, 39-42.

Mishra and Mulani (2021). Corticosteroids for COVID-19: the search for an optimum duration of therapy. The Lancet. Respiratory Medicine, 9(1), e8.

Moorthy et al (2021). SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. Journal of Maxillofacial and Oral Surgery, 1-8.

Muthu et al (2021). Has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis. Clinical Microbiology and Infection.

Onder et al (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama, 323(18), 1775-1776.

Panchanatheeswaran et al (2021). Thoracic mucormycosis in immunocompetent patients. Journal of Cardiac Surgery, 36(4), 1183-1188.

Park et al (2021). Mucormycosis originated total maxillary and cranial base osteonecrosis: a possible misdiagnosis to malignancy. BMC Oral Health, 21(1), 1-6.

Prescott and Rice (2020). Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. Jama, 324(13), 1292-1295.

Ramanathan et al (2020). Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. The Lancet Respiratory Medicine, 8(5), 518-526.

Ranjbar et al (2021). Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC infectious diseases, 21(1), 1-8.

Saad et al (2020). Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). Obstetrics & Gynecology, 136(4), 823-826.

Saldanha et al (2021). of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian Journal of Otolaryngology and Head & Neck Surgery, 1-4.

Singh et al (2021). Diabetes and rhino-orbito-cerebral mucormycosis–A deadly duo. Journal of Diabetes & Metabolic Disorders, 1-7.

Singh et al (2021). Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

Sittig et al (2021). Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib. IDCases, 24, e01120.

Steinbrink and Miceli  (2021). Mucormycosis. Infectious Disease Clinics, 35(2), 435-452.

Sterne et al (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. Jama, 324(13), 1330-1341.

Stryker et al (2021). Successful Multi-Modal Treatment of Endobronchial Mucormycosis Infection of Native Lung after Lung Transplant. The Journal of Heart and Lung Transplantation, 40(4), S343-S344.

Szarpak (2021). Mucormycosis-a serious threat in the COVID-19 pandemic?. Journal of Infection.

Tlayjeh et al (2020). Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. Journal of infection and public health.

Veisi et al (2021). Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. European Journal of Ophthalmology, 11206721211009450.

Verma and Bali (2021). COVID-19 and Mucormycosis of the Craniofacial skeleton: Causal, Contributory or Coincidental?.

Werthman-Ehrenreich  (2021). Mucormycosis with orbital compartment syndrome in a patient with COVID-19. The American Journal of Emergency Medicine, 42, 264-e5.

Zurl et al (2021). Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. Journal of Fungi, 7(2), 88.